Future of underwriting forum
How medical expertise shapes underwriting transformation
Business people working on a glass wall looking over their notes for the challenges in the life insurance industry
© PeopleImages / Getty Images

In this Q&A series, Tim Morant, Chief Risk Assessment Officer at Munich Re Life US, explores the rapidly evolving risk assessment landscape with industry experts. 

Dr. Gina Guzman (GG) is Vice-President and Chief Medical Director at Munich Re Life US. With over 25 years of experience in insurance medicine, Dr. Guzman has a deep understanding of risk assessment and plays a key role in investigating medical advances as they relate to driving innovation in life insurance.  

Can you provide an overview of your career path?

GG: I come from a family of health care professionals. My father is a doctor, my mother is a nurse, and my older sister is a neonatal ICU nurse. My grandfather was a surgeon, my grandmother a pharmacist, and I also have several extended family members with careers in nursing, pharmacy, and medical equipment sales. You can say that medicine is in my blood, so it’s not surprising that I chose a career in this field.

I completed all my post-graduate training in downtown Chicago, where I also met my husband. After completing medical school and a residency in Internal Medicine, I got married and worked as a clinical internist in the western suburbs of Chicago. However, work was grueling, I never saw my husband, and I was getting burned out quickly. A friend of a friend suggested I look into Insurance Medicine. I had no idea what that entailed, but shortly after, I was on the phone with the Chief Medical Officer of CNA Life Re getting the scoop. I was fascinated by the intermixing of my medical knowledge with the business of life insurance, but at that time, there were no jobs available.

As luck would have it, I was called back a few months later. CNA Life Re was being sold to Munich Re, and a medical director position had opened up. I was encouraged to interview despite having no experience in Insurance Medicine. I took a leap of faith and interviewed. Fortunately, they gave me a chance and I’ve been with Munich Re now for over 25 years! It’s the best decision I have ever made.

Can you think of a time or opportunity that had a major impact on the trajectory of your career?

GG: To be honest, it was the year 2000 when I made the change from Internal Medicine to Insurance Medicine. I thought I would miss patient care, but I truly don’t. I was glad to give up all the paperwork and move to a career where my medical knowledge is used to expand insurability to people who need and deserve life and disability insurance. I spent the first five years of my career in “development” mode, learning everything I could about the blend of insurance and medicine. I became Board Certified as a Diplomat of the Board of Insurance Medicine (DBIM) in 2004, Fellow of the Academy of Life Underwriting (FALU) in 2012, Fellow of the Life Management Institute (FLMI) in 2014, and Fellow of the American Academy of Insurance Medicine (FAAIM) in 2018. I continue to be a lifelong learner, using my time to focus on the latest medical advancements, changes in healthcare technology, and researching how these impact mortality and morbidity.  

    With multiple breakthroughs in medicine and healthcare technology, we now have a unique opportunity to redefine underwriting and expand insurability.
    Dr. Gina Guzman
    Munich Re Life US

    What key market underwriting trends excite you about where things might be headed?

    GG: With multiple breakthroughs in medicine and healthcare technology, we now have a unique opportunity to redefine underwriting and expand insurability. For example, genomics and artificial intelligence (AI) are two of the most transformative forces in medicine today. AI is expected to improve cancer mortality rates by enabling earlier detection, more accurate diagnosis, and personalized treatment strategies. This is evidenced by the growing use of AI-powered deep learning models to analyze imaging and pathology tests with greater precision. In addition, AI’s rapid analysis of genomic data offers a more personalized approach to cancer treatment, often leading to improvements in survival rates. These advancements translate to more accurate underwriting risk assessments, expanded insurability for applicants, and the placement of more profitable business on our books – a win-win for both applicants and life insurance companies. And we’re only seeing the tip of the iceberg as to the future benefits of the GLP-1 class of medications beyond metabolic risks and obesity.  

    What can we do as an industry to react to or stay ahead of these trends?

    GG: Medical advancements are occurring at a much faster pace, so it is imperative that insurers maintain a dedicated, vigilant, and knowledgeable medical team (and/or a good reinsurance partnership) to keep abreast of the medical literature. We are also seeing more collaboration between pricing, underwriting, and data scientists, and this needs to continue.

    What are some of the major challenges you see that the industry is facing or will face in the near term?

    GG: I think one major challenge will be keeping up with AI and the wide-ranging implications it will have on our business. AI will produce efficiencies in how we operate, and companies will need to adapt their IT, legal, and underwriting processes accordingly. Underwriting in the future will look very different than it does today. 

    What does it mean to you to “get the basics right,” and why would that be important in underwriting and risk assessment?

    GG: When I think about getting the basics right, I think about the medical aspects of underwriting and risk assessment. This includes using the most up-to-date medical literature to calculate mortality ratios and ensuring the correct prognostic factors are taken into account. The basis of an underwriting assessment must come from accurate medical evidence in order for the pricing to be appropriate. This is the only way to put profitable business on the books. 

    Contact the authors

    Tim Morant
    Tim Morant
    Chief Risk Assessment Officer
    Munich Re Life US
    Gina Guzman
    Dr. Gina Guzman
    Vice President & Chief Medical Director
    Munich Re Life US

    Newsletter

    Subscribe to our newsletter for the latest industry research, insights on life and health-related topics, and relevant Munich Re Life US updates. Join today and stay connected with our business.
      alt txt

      properties.trackTitle

      properties.trackSubtitle

      0:00
      0:00